A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

Bispecific T-cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL-1 trial and was recently approved by the Food and Drug Administration and the European Medicines Agency. However, treatment under real-world conditions may not represent patient characteristics in clinical trials with restricted enrollment criteria. We performed a retrospective real-world analysis including 138 RRMM patients treated with talquetamab at 21 German centers. Of evaluable patients, 43% had ISS stage III, 37% had extraosseous disease, and 48% had high-risk cytogenetics. After a median of six prior therapy lines, 58% of patients would not have been eligible for MonumenTAL-1. With a median follow-up of 8.2 months, we observed an overall response rate of 65% and a median progression-free survival of 6.4 months (95% confidence interval 5.1-9.0). Prior BTCE exposure, ISS stage III, extraosseous disease, and penta-drug refractory disease were associated with unfavorable outcomes. Grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 5.1% and 1.5% of patients, respectively. In summary, our real-world study confirms the efficacy and safety of talquetamab, despite a high proportion of patient- and disease-related risk factors. These results support its use as bridging or long-term treatment, even in advanced stages.

Authors

Institutions

Publication Details

Journal
HemaSphere
Published
2025-04-01
DOI
https://doi.org/10.1002/hem3.70114
Citations
10
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
17.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

Marion Högner, Igor Age Kos, Christine Hanoun, Karolin Trautmann‐Grill et al.
10 citations
HemaSphere
Multiple Myeloma Research and Treatments
17.70
article

A German multicenter real‐world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma

Marion Högner, Igor Age Kos, Christine Hanoun, Karolin Trautmann‐Grill, Leo Rasche, Jan Krönke, Carsten Müller‐Tidow, Franziska Brünner, Annamaria Brioli, Jan Frenking, Sarah Goldman‐Mazur, Sebastian Theurich, Christine Riedhammer, Deniz Gezer, Romans Zukovs, Cyrus Khandanpour, Christian Michel, Britta Besemer, Raphael Teipel, Florian C. Bassermann, Mathias Hänel, Miriam Kull, Theo Leitner, Moritz Bewarder, Marc S. Raab, Maria Dampmann, Jan Braune, Ralph Wäsch, Ivana von Metzler, Roland Fenk, Maximilian Merz, Katja Kolditz, Valentine Landrin
article en
10 citations

Abstract

Bispecific T-cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL-1 trial and was recently approved by the Food and Drug Administration and the European Medicines Agency. However, treatment under real-world conditions may not represent patient characteristics in clinical trials with restricted enrollment criteria. We performed a retrospective real-world analysis including 138 RRMM patients treated with talquetamab at 21 German centers. Of evaluable patients, 43% had ISS stage III, 37% had extraosseous disease, and 48% had high-risk cytogenetics. After a median of six prior therapy lines, 58% of patients would not have been eligible for MonumenTAL-1. With a median follow-up of 8.2 months, we observed an overall response rate of 65% and a median progression-free survival of 6.4 months (95% confidence interval 5.1-9.0). Prior BTCE exposure, ISS stage III, extraosseous disease, and penta-drug refractory disease were associated with unfavorable outcomes. Grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 5.1% and 1.5% of patients, respectively. In summary, our real-world study confirms the efficacy and safety of talquetamab, despite a high proportion of patient- and disease-related risk factors. These results support its use as bridging or long-term treatment, even in advanced stages.

HemaSphereVol. 9(4)
Goethe University Frankfurt (DE), University of Freiburg (DE), German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), Universitätsmedizin Greifswald (DE), University Hospital Heidelberg (DE), LMU Klinikum (DE), Medizinische Hochschule Hannover (DE), Düsseldorf University Hospital (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), National Center for Tumor Diseases (DE), Essen University Hospital (DE), Universitätsklinikum Aachen (DE), German Marine Research Consortium (DE), University Children's Hospital Tübingen (DE), Universitätsklinikum Würzburg (DE), University Hospital Frankfurt (DE), University Hospital in Halle (DE), University Hospital Ulm (DE), University Hospital Carl Gustav Carus (DE), Klinikum Chemnitz (DE), Deutsches Konsortium für Translationale Krebsforschung (DE), Heinrich Heine University Düsseldorf (DE), Technical University of Munich (DE), Charité - Universitätsmedizin Berlin (DE), Ludwig-Maximilians-Universität München (DE), Saarland University (DE), University of Lübeck (DE)
Falk Foundation, Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceuticals, BeiGene, Incyte, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Swedish Orphan Biovitrum, Cilag
Good health and well-being
Openalex Percentile: Top 1%
Multiple Myeloma Research and Treatments
17.70
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.